Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -70.2%. (2009–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $2M | $9M | $7M | $7M | $109M | — | — | — | — | — |
| Enterprise Value | $-2856863 | $-3630762 | $5M | $4M | $-335282 | $103M | — | — | — | — | — |
| P/E Ratio → | -0.52 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.30 | 0.32 | 2.46 | 2.46 | 1.21 | 16.64 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | 32489.12 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -70.2% | -70.2% | -128.7% | -202.2% | -23.7% | -24.5% | — | — | — | — | — |
| ROA | -64.4% | -64.4% | -108.2% | -146.3% | -19.6% | -24.1% | — | -639.2% | -482.5% | -797.4% | -1695.2% |
| ROIC | -2405.1% | -2405.1% | -16515.7% | — | — | — | — | — | — | — | — |
| ROCE | -73.0% | -73.0% | -132.0% | -213.0% | -58.5% | -16.8% | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -0.95 | -1.04 | -1.27 | -1.02 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | -20652.99 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1.03 | -1.00 | -0.83 | -2.51 | -2.27 | -0.59 | -8.89 |
Net cash position: cash ($5M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.85 | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 | — | 0.05 | 0.11 | 0.83 | 0.47 |
| Quick Ratio | 13.85 | 13.85 | 10.22 | 4.50 | 3.33 | 66.81 | — | 0.05 | 0.11 | 0.83 | 0.47 |
| Cash Ratio | 12.74 | 12.74 | 8.80 | 3.64 | 2.96 | 66.81 | — | 0.04 | 0.10 | 0.72 | 0.41 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 37.5% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 37.5% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $1M | $2M | $263137 | $47658 | $43127 | $51138 | $51138 | $1396 | $1081 | $1045 |
Binary clinical trial failure
As reported in recent financial data, BBLG trades at a price-to-book ratio of 0.29, which suggests that the market is heavily discounting the company's intellectual property assets due to the significant probability of clinical failure or the necessity for further dilutive equity financing to reach commercialization.
The current valuation reflects an option-like profile where the market assigns little value to the underlying technology until regulatory milestones are met. Investors should note that traditional valuation multiples like P/E or EV/EBITDA are non-meaningful given the pre-revenue status, making the P/B ratio the primary, albeit limited, metric for assessing the floor of the enterprise value.
Based on historical financial statements, BBLG has consistently reported negative ROIC figures, including a -6.6% return in 2026Q1, which highlights the ongoing erosion of invested capital as the firm prioritizes clinical trial expenditures over the generation of any immediate economic returns on its core NELL-1 technology.
The persistent negative returns on capital are a structural feature of the company's current development phase rather than a reflection of operational mismanagement. This trend suggests that until the company transitions to a commercial stage, capital efficiency will remain secondary to the binary objective of achieving FDA approval.
According to recent quarterly filings, BBLG maintains a current ratio of 16.09 as of 2026Q1, yet this high figure is misleading as it reflects a rapidly depleting cash balance rather than operational strength, indicating a precarious liquidity position that warrants close monitoring for potential near-term capital raises.
While the current ratio appears robust, the absolute cash position of $5.3 million is insufficient to support long-term clinical development without external intervention. The lack of revenue-generating assets means that the company's liquidity is entirely dependent on the timing and terms of future equity issuances, which may further dilute existing shareholders.
As indicated by the company's financial disclosures, the current ratio is the most commonly misapplied metric for BBLG, as it obscures the reality that the firm's high liquidity levels are merely a function of recent capital raises rather than an indicator of sustainable operational health or solvency.
Analysts should instead focus on the cash burn rate and the remaining operational runway in months, as these metrics provide a more accurate assessment of the company's survival risk. Relying on standard liquidity ratios in a pre-revenue biotech context risks overestimating the company's financial stability and underestimating the urgency of its funding requirements.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BBLG stock.
Bone Biologics Corporation's current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Bone Biologics Corporation's return on equity (ROE) is -70.2%. The historical average is -89.8%.
Based on historical data, Bone Biologics Corporation is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.